CleveXel, Dynamix Enter RA Development Pact

Clevexel Pharma has entered into an agreement with Dynamix Pharmaceuticals for the development of a dual mechanism SYK/JAK molecule in rheumatoid arthritis (RA). The orally active SYK/JAK product is part of Dynamix’ lead development program and offers a new mechanism of action. Oral administration is of great interest as current treatments are mainly only injectable. The companies aim to bring the RA project to a clinical proof-of-concept stage, with preclinical development planned for early 2014.
 
“We are happy to collaborate with CleveXel and to gain access to their development expertise”, said Batsheva Elran, managing partner at Opal Ventures and chairman of Dynamix. “This collaboration is an excellent opportunity to share the risks in developing an innovative project in inflammatory diseases and to address unmet needs,” said Dr. Itzchak Angel, chief executive officer of Angel Pharmaceutical Consulting and Technologies, who represent Dynamix Pharmaceuticals in this partnership.
 
 
“For CleveXel, the partnership will innovate in inflammatory disease, potentially also in oncology,” said Christian Bloy, chief executive officer of CleveXel. “JAK3 and SYK represent new targets that are extremely interesting in order to develop an orally administered product. CleveXel Pharma is very happy to be part of this leading project with Dynamix.”